Prophylactic neuroprotection against stroke: Low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function

Journal of Cerebral Blood Flow and Metabolism

Volumn 31, Issue 6, 2011, Pages 1412-1423

  Zhao, Yanxin ^a   Rempe, David A ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

HIF 1; hypoxia; ischemia; stroke

Indexed keywords

DEFERASIROX; DEFEROXAMINE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; HAPLOINSUFFICIENCY; HUMAN; LOW DRUG DOSE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRANSGENIC MOUSE;

ANIMALS; ASTROCYTES; BENZOIC ACIDS; BRAIN; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DEFEROXAMINE; ERYTHROPOIETIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE DELETION; HYPOXIA-INDUCIBLE FACTOR 1; IRON CHELATING AGENTS; MICE; MICE, KNOCKOUT; NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; STROKE; TRIAZOLES;

EID: 79957948980     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2010.230     Document Type: Article

References (37)

1. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA (2001) Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregu-lates endothelial nitric oxide synthase in mice. Stroke 32:980-6
2. Baranova O, Miranda LF, Pichiule P, Dragatsis I, Johnson RS, Chavez JC (2007) Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci 27:6320-32 (Pubitemid 46890035)
3. Bruin GJ, Faller T, Wiegand H, Schweitzer A, Nick H, Schneider J, Boernsen KO, Waldmeier F (2008) Pharma-cokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos 36:2523-38
4. Cai Z, Zhong H, Bosch-Marce M, Fox-Talbot K, Wang L, Wei C, Trush MA, Semenza GL (2008) Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc Res 77:463-70 (Pubitemid 351197653)
5. Cappellini MD (2008) Long-term efficacy and safety of deferasirox. Blood Rev 22(Suppl 2):S35-41
6. Chavez JC, Baranova O, Lin J, Pichiule P (2006) The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. J Neurosci 26:9471-81 (Pubitemid 44396860)
7. Cheng YD, Al-Khoury L, Zivin JA (2004) Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 1:36-45 (Pubitemid 46589340)
8. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW (2008) Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 7:875-84
9. Fisher M, Jonas S, Sacco RL, Jones S (1994) Prophylactic neuroprotection for cerebral ischemia. Stroke 25: 1075-80 (Pubitemid 24130323)
10. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA, van de Wiel MA, Belien JA, van Diest PJ, van der Wall E (2005) Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 206: 291-304 (Pubitemid 40903193)
11. Hill MD, Yiannakoulias N, Jeerakathil T, Tu JV, Svenson LW, Schopflocher DP (2004) The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology 62:2015-20 (Pubitemid 38738214)
12. Ito T, Yamakawa H, Bregonzio C, Terron JA, Falcon-Neri A, Saavedra JM (2002) Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 33:2297-303 (Pubitemid 35014646)
13. Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, Sidney S (2007) Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 369:283-92 (Pubitemid 46136488)
14. Kleindorfer D, Panagos P, Pancioli A, Khoury J, Kissela B, Woo D, Schneider A, Alwell K, Jauch E, Miller R, Moomaw C, Shukla R, Broderick JP (2005) Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 36:720-3
15. Labiche LA, Grotta JC (2004) Clinical trials for cytoprotec-tion in stroke. NeuroRx 1:46-70
16. Lin TN, He YY, Wu G, Khan M, Hsu CY (1993) Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke 24:117-21 (Pubitemid 23014393)
17. Lukic-Panin V, Kamiya T, Zhang H, Hayashi T, Tsuchiya A, Sehara Y, Deguchi K, Yamashita T, Abe K (2007) Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats. Brain Res 1176:143-50 (Pubitemid 47553120)
18. Malhotra S, Savitz SI, Ocava L, Rosenbaum DM (2006) Ischemic preconditioning is mediated by erythropoietin through PI-3 kinase signaling in an animal model of transient ischemic attack. J Neurosci Res 83:19-27 (Pubitemid 43062006)
19. Nagel S, Papadakis M, Chen R, Hoyte LC, Brooks KJ, Gallichan D, Sibson NR, Pugh C, Buchan AM (2010) Neuroprotection by dimethyloxalylglycine following permanent and transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1-12
20. Niatsetskaya Z, Basso M, Speer RE, McConoughey SJ, Coppola G, Ma TC, Ratan RR (2010) HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease. Antioxid Redox Signal 12:435-43
21. Prass K, Scharff A, Ruscher K, Lowl D, Muselmann C, Victorov I, Kapinya K, Dirnagl U, Meisel A (2003) Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 34:1981-6 (Pubitemid 36944794)
22. Ratan RR, Siddiq A, Aminova L, Lange PS, Langley B, Ayoub I, Gensert J, Chavez J (2004) Translation of ischemic preconditioning to the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel targets for stroke therapy. Stroke 35:2687-9 (Pubitemid 39458369)
23. Rempe D, Vangeison G, Hamilton J, Li Y, Jepson M, Federoff HJ (2006) Synapsin I Cre transgene expression in male mice produces germline recombination in progeny. Genesis 44:44-9 (Pubitemid 43222210)
24. Rempe DA, Lelli KM, Vangeison G, Johnson RS, Federoff HJ (2007) In cultured astrocytes, p53 and MDM2 do not alter hypoxia-inducible factor-1\{alpha\} functi. J Biol Chem 282:16187-201 (Pubitemid 47100340)
25. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, Johnson RS (2000) Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 60:4010-5 (Pubitemid 30636574)
26. Savitz SI, Fisher M (2007) Prophylactic neuroprotection. Curr Drug Targets 8:846-9 (Pubitemid 47163395)
27. Semenza GL (2000) HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88:1474-80 (Pubitemid 30217451)
28. Semenza GL (2008) Mitochondrial autophagy: life and breath of the cell. Autophagy 4:534-6 (Pubitemid 351705156)
29. Siddiq A, Aminova LR, Troy CM, Suh K, Messer Z, Semenza GL, Ratan RR (2009) Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways. J Neurosci 29:8828-38
30. Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, Patton SM, Connor JR, Cherny RA, Volitakis I, Bush AI, Langsetmo I, Seeley T, Gunzler V, Ratan RR (2005) Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 280: 41732-43 (Pubitemid 41832236)
31. Thijs VN, Albers GW (2000) Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrom-botic therapy. Neurology 55:490-7 (Pubitemid 30647243)
32. Vengellur A, Woods BG, Ryan HE, Johnson RS, LaPres JJ (2003) Gene expression profiling of the hypoxia signaling pathway in hypoxia-inducible factor 1alpha null mouse embryonic fibroblasts. Gene Expr 11:181-97 (Pubitemid 37516650)
33. Weidemann A, Kerdiles YM, Knaup KX, Rafie CA, Boutin AT, Stockmann C, Takeda N, Scadeng M, Shih AY, Haase VH, Simon MC, Kleinfeld D, Johnson RS (2009) The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. J Clin Invest 119:3373-83
34. Zaman K, Ryu H, Hall D, O'Donovan K, Lin K-I, Miller MP, Marquis JC, Baraban JM, Semenza GL, Ratan RR (1999) Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21Waf1/cip1, and erythropoietin. J Neurosci 19:9821-30 (Pubitemid 30226655)
35. Zhu Y, Romero MI, Ghosh P, Ye Z, Charnay P, Rushing EJ, Marth JD, Parada LF (2001) Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev 15:859-76 (Pubitemid 32295067)
36. Zhu Y, Zhang L, Gidday JM (2008) Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance. J Ocul Pharmacol Ther 24:527-35
37. Zhuo L, Theis M, Alvarez-Maya I, Brenner M, Willecke K, Messing A (2001) hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. Genesis 31:85-94 (Pubitemid 33064319)